Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY PIAZZA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1326006818
CMS profile
286283
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$103,222.33

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $78,602.47 54
E.R. Squibb & Sons, L.L.C. $10,688.86 7
PFIZER INC. $6,125.00 2
Regeneron Pharmaceuticals, Inc. $5,406.00 6
Penumbra, Inc. $2,400.00 3

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY PIAZZA

NPI 1326006818 · CMS profile ID 286283

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326006818?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY PIAZZA, NPI 1326006818, CMS profile ID 286283. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326006818?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GREGORY PIAZZA, NPI 1326006818, CMS profile ID 286283. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326006818?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GREGORY PIAZZA, NPI 1326006818, CMS profile ID 286283, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1326006818?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $103,222.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–72 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $124.9904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181203810 CMS
Boston Scientific Corporation $210.1504/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203818 CMS
Penumbra, Inc. $600.0004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1218184042 CMS
Regeneron Pharmaceuticals, Inc. $901.0004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213242251 CMS
Boston Scientific Corporation $350.0003/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1181203788 CMS
Boston Scientific Corporation $1,050.0003/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1181203790 CMS
Boston Scientific Corporation $1,400.0003/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181203784 CMS
Boston Scientific Corporation $350.0003/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181203786 CMS
Boston Scientific Corporation $81.8103/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181203792 CMS
Boston Scientific Corporation $2,812.5003/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181203860 CMS
PFIZER INC. $1,000.0003/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1228887749 CMS
PFIZER INC. $5,125.0003/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1228887919 CMS
Regeneron Pharmaceuticals, Inc. $901.0002/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213242247 CMS
Regeneron Pharmaceuticals, Inc. $901.0002/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213242249 CMS
Boston Scientific Corporation $123.0002/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203770 CMS
Boston Scientific Corporation $109.1801/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181203768 CMS
Boston Scientific Corporation $182.9201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181203774 CMS
Boston Scientific Corporation $180.5701/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203776 CMS
Boston Scientific Corporation $27.7501/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203778 CMS
Boston Scientific Corporation $158.0201/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203772 CMS
Boston Scientific Corporation $208.9401/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203780 CMS
Boston Scientific Corporation $9,949.4101/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181203782 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,657.04 33
PY2020 $49,320.73 31
PY2021 $49,132.10 18
PY2022 $57,834.57 48
PY2023 $28,542.46 29
PY2024 $25,550.94 27
PY2025 $103,222.33 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $787,261.18 92
PY2024 Recipient $1,294.84 8
PY2024 Principal investigator $564,820.30 7
PY2023 Principal investigator $735,202.40 8
PY2022 Principal investigator $1,315,142.10 17
PY2021 Principal investigator $858,771.32 15
PY2020 Principal investigator $409,532.89 33
PY2019 Principal investigator $341,209.57 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

92 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 12/30/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 12/30/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 12/30/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 12/30/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 12/30/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,549.07 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.69 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,207.65 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $247.86 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.69 12/22/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 11/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
Provider- and Patient-Facing Alert-Based Computerized Decision Support for Identification and Management of Patients with Familial Hypercholesterolemia (FH-ALERT Trial) No dispute reported 06/30/2026 1184125616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,111.61 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,549.07 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,617.11 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,111.61 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,549.07 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.69 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,308.39 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,308.39 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,111.61 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,207.65 11/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.69 10/31/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 10/31/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.40 10/31/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $247.86 10/31/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 10/31/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 10/03/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 10/03/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,111.61 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,207.65 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,549.07 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,617.11 09/17/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.85 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.75 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.40 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 09/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,207.65 08/28/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.69 08/28/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,549.07 08/28/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125538
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $140,464.94 08/01/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
Extended-Duration Low-Dose Apixaban to Prevent Recurrence in Provoked Venous Thromboembolism No dispute reported 06/30/2026 1236001665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109,224.36 07/28/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
Provider- and Patient-Facing Alert-Based Computerized Decision Support for Identification and Management of Patients with Familial Hypercholesterolemia (FH-ALERT Trial) No dispute reported 06/30/2026 1184125532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,684.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,500.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,288.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 06/27/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 06/27/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,111.61 06/27/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PERIPHERALLY INSERTED CENTRAL CATHETER (ROXI-CATH) No dispute reported 06/30/2026 1184125516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259,407.86 06/16/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
Provider- and Patient-Facing Alert-Based Computerized Decision Support for Identification and Management of Patients with Familial Hypercholesterolemia (FH-ALERT Trial) No dispute reported 06/30/2026 1184125510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,875.00 02/19/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
Provider- and Patient-Facing Alert-Based Computerized Decision Support for Identification and Management of Patients with Familial Hypercholesterolemia (FH-ALERT Trial) No dispute reported 06/30/2026 1184125290
Principal investigator 1 Boston Scientific Corporation $50,716.00 01/23/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Clinical Study of patients with PE Receiving Anticoagulation Alone and a Similar Analysis of the OPTALYSE-PE Trial No dispute reported 06/30/2026 1207578157
Principal investigator 1 Boston Scientific Corporation $53,330.35 01/23/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Clinical Study of patients with PE Receiving Anticoagulation Alone and a Similar Analysis of the OPTALYSE-PE Trial No dispute reported 06/30/2026 1207578159
Principal investigator 1 Boston Scientific Corporation $50,716.00 01/23/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Clinical Study of patients with PE Receiving Anticoagulation Alone and a Similar Analysis of the OPTALYSE-PE Trial No dispute reported 06/30/2026 1207578161